Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EPIX NASDAQ:HGEN NASDAQ:MNKD NASDAQ:PRTA NASDAQ:VERU On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEPIXESSA Pharma$1.71-2.3%$1.70$1.40▼$7.88$77.68M1.56340,146 shs72,074 shsHGENHumanigen$0.00$0.00▼$0.24$24K-1.043.26 million shs2.06 million shsMNKDMannKind$3.77-0.8%$4.10$3.51▼$7.63$1.15B0.962.44 million shs1.82 million shsPRTAProthena$6.40-2.6%$6.13$4.32▼$25.42$353.64M0.01801,542 shs569,147 shsVERUVeru$0.60+3.0%$0.57$0.45▼$1.42$85.49M-0.751.93 million shs1.56 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEPIXESSA Pharma-2.29%-1.44%+1.18%+8.23%-67.37%HGENHumanigen0.00%0.00%0.00%0.00%0.00%MNKDMannKind-0.79%+4.58%-2.84%-19.10%-31.83%PRTAProthena-2.59%-1.08%+25.49%-37.38%-69.54%VERUVeru+2.97%+0.08%-10.71%+10.65%-31.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEPIXESSA Pharma1.3722 of 5 stars2.02.00.00.00.62.51.3HGENHumanigenN/AN/AN/AN/AN/AN/AN/AN/AMNKDMannKind2.2638 of 5 stars3.60.00.00.00.51.71.9PRTAProthena3.56 of 5 stars4.24.00.00.01.01.71.3VERUVeru2.2133 of 5 stars3.54.00.00.00.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEPIXESSA Pharma 2.00Hold$2.0016.96% UpsideHGENHumanigen 0.00N/AN/AN/AMNKDMannKind 3.29Buy$10.33174.09% UpsidePRTAProthena 2.33Hold$31.50392.19% UpsideVERUVeru 3.00Buy$4.00566.11% UpsideCurrent Analyst Ratings BreakdownLatest EPIX, PRTA, VERU, HGEN, and MNKD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/20/2025PRTAProthenaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/28/2025PRTAProthenaBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform5/27/2025PRTAProthenaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$110.00 ➝ $81.005/27/2025PRTAProthenaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$78.00 ➝ $29.005/27/2025PRTAProthenaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral5/27/2025PRTAProthenaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$6.005/27/2025PRTAProthenaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/27/2025PRTAProthenaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $14.005/27/2025PRTAProthenaChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $18.005/13/2025PRTAProthenaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEPIXESSA PharmaN/AN/AN/AN/A$2.81 per shareN/AHGENHumanigen$1.70M0.00N/AN/A($0.45) per share0.00MNKDMannKind$285.50M4.01$0.14 per share27.38($0.29) per share-13.00PRTAProthena$135.16M2.55N/AN/A$9.05 per share0.71VERUVeru$16.89M5.21N/AN/A$0.22 per share2.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEPIXESSA Pharma-$28.54M-$0.63N/AN/AN/AN/A-23.48%-22.86%8/4/2025 (Estimated)HGENHumanigen-$70.73MN/A0.00N/AN/AN/AN/AN/AN/AMNKDMannKind$27.59M$0.1037.7016.39N/A10.12%-32.41%10.85%8/6/2025 (Estimated)PRTAProthena-$122.31M-$2.08N/AN/AN/A-79.94%-21.61%-19.32%8/6/2025 (Estimated)VERUVeru-$37.80M-$0.24N/AN/AN/AN/A-128.51%-76.51%8/6/2025 (Estimated)Latest EPIX, PRTA, VERU, HGEN, and MNKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025MNKDMannKind$0.04N/AN/AN/A$77.82 millionN/A8/4/2025Q3 2025EPIXESSA Pharma-$0.2430N/AN/AN/AN/AN/A5/8/2025Q2 2025EPIXESSA Pharma-$0.19-$0.14+$0.05-$0.14N/AN/A5/8/2025Q1 2025MNKDMannKind$0.03$0.04+$0.01$0.04$75.86 million$78.35 million5/8/2025Q1 2025PRTAProthena-$0.92-$1.12-$0.20-$1.12$8.18 million$2.83 million5/8/2025Q2 2025VERUVeru-$0.06-$0.05+$0.01-$0.05$0.73 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEPIXESSA PharmaN/AN/AN/AN/AN/AHGENHumanigenN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/APRTAProthenaN/AN/AN/AN/AN/AVERUVeruN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEPIXESSA PharmaN/A67.1567.15HGENHumanigenN/AN/AN/AMNKDMannKindN/A2.362.11PRTAProthenaN/A9.009.00VERUVeruN/A3.803.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEPIXESSA Pharma75.12%HGENHumanigen4.55%MNKDMannKind49.55%PRTAProthena97.08%VERUVeru47.16%Insider OwnershipCompanyInsider OwnershipEPIXESSA Pharma15.50%HGENHumanigen21.70%MNKDMannKind2.70%PRTAProthena9.20%VERUVeru15.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEPIXESSA Pharma5044.39 million37.51 millionOptionableHGENHumanigen6119.08 million93.24 millionNo DataMNKDMannKind400303.93 million295.73 millionOptionablePRTAProthena13053.83 million48.88 millionOptionableVERUVeru230146.58 million124.30 millionOptionableEPIX, PRTA, VERU, HGEN, and MNKD HeadlinesRecent News About These CompaniesVeru And Two Other Penny Stocks To ConsiderJune 26, 2025 | finance.yahoo.comVeru Inc (FMW.DU)June 26, 2025 | nz.finance.yahoo.comVeru reports positive results for enobosarm in weight management studyJune 26, 2025 | uk.investing.comWhy Veru Inc. Is Rising In Pre-market? - NasdaqJune 26, 2025 | nasdaq.comVeru (NASDAQ:VERU) Stock Price Crosses Below 200-Day Moving Average - Here's What HappenedJune 25, 2025 | marketbeat.comOne Veru Insider Raised Stake By 150% In Previous YearJune 22, 2025 | finance.yahoo.comScholar Rock drug preserves muscle in obesity trialJune 18, 2025 | yahoo.comTraders Buy High Volume of Put Options on Veru (NASDAQ:VERU)June 17, 2025 | marketbeat.comVeru (NASDAQ:VERU) Stock Crosses Below 200-Day Moving Average - Here's WhyJune 17, 2025 | marketbeat.comVeru Inc. to Engage with Investors at BTIG Obesity Health Forum on June 18, 2025June 11, 2025 | quiverquant.comQVeru to Participate in the Virtual BTIG Obesity Health ForumJune 11, 2025 | globenewswire.comBeyond Meat, Plby among consumer staple names set to join Russell Microcap Index, Veru, Vital Farms to leaveMay 30, 2025 | seekingalpha.comVeru’s obesity drug roughly as safe as Wegovy; Keros’ board fightMay 28, 2025 | endpts.comEMuscle-sparing obesity drug safe for Phase 3 trial, Veru saysMay 28, 2025 | yahoo.comVeru Inc. Announce Positive Topline Safety Data from Phase 2b QUALITY Study of Enobosarm Combined with SemaglutideMay 28, 2025 | quiverquant.comQVeru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide AloneMay 28, 2025 | globenewswire.comVeru: Saving Muscle Mass Amidst The GLP-1 Drug BoomMay 26, 2025 | seekingalpha.comYoungsters at Dunstable school hear about the dangers of knife crimeMay 22, 2025 | msn.comVeru Inc.: Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program ProgressMay 8, 2025 | finanznachrichten.deVeru signals Q3 2025 regulatory clarity for enobosarm Phase 3 trialMay 8, 2025 | msn.comVeru Inc. (VERU) Q2 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEPIX, PRTA, VERU, HGEN, and MNKD Company DescriptionsESSA Pharma NASDAQ:EPIX$1.71 -0.04 (-2.29%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.72 +0.01 (+0.58%) As of 07/11/2025 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.Humanigen NASDAQ:HGENHumanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1, as well as treats a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey. On January 3, 2024, Humanigen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.MannKind NASDAQ:MNKD$3.77 -0.03 (-0.79%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$3.78 +0.01 (+0.16%) As of 07/11/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.Prothena NASDAQ:PRTA$6.40 -0.17 (-2.59%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$6.26 -0.14 (-2.17%) As of 07/11/2025 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.Veru NASDAQ:VERU$0.60 +0.02 (+2.97%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$0.59 -0.01 (-1.75%) As of 07/11/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
